Search alternatives:
treatment decreased » treatment increases (Expand Search)
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
b marked » _ marked (Expand Search), _ market (Expand Search), _ marker (Expand Search)
a marked » a marker (Expand Search), _ marked (Expand Search), a market (Expand Search)
Showing 1 - 7 results of 7 for search '(( a ((largest decrease) OR (treatment decreased)) ) OR ( ((b marked) OR (a marked)) decrease ))~', query time: 0.36s Refine Results
  1. 1
    CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i><sup><i>ECKO</i></sup> mice and lesions in the retina of <i>Ccm2</i><sup><i>ECKO</i></sup> mice.

    CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i><sup><i>ECKO</i></sup> mice and lesions in the retina of <i>Ccm2</i><sup><i>ECKO</i></sup> mice. by Jia Li (160557)

    Published 2020
    Save to List
    Saved in:
  2. 2
    Image_3_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif

    Image_3_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

    Published 2022
    “…Next with the largest cohort of patients with DNMT3A R882 mutant MDS known to date from multiple institutions, DNMT3A R882 mutant MDS cases were shown to have more severe leukopenia, enriched SRSF2 and IDH2 mutations, increased cases with excess blasts (47% vs 22.5%, p=.004), markedly increased risk of AML transformation (25.8%, vs. 1.7%, p=.0001) and a worse progression-free survival (PFS) (median 20.3, vs. >50 months, p=.009) than non-R882 mutant MDS cases. …”
    Save to List
    Saved in:
  3. 3
    Image_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif

    Image_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

    Published 2022
    “…Next with the largest cohort of patients with DNMT3A R882 mutant MDS known to date from multiple institutions, DNMT3A R882 mutant MDS cases were shown to have more severe leukopenia, enriched SRSF2 and IDH2 mutations, increased cases with excess blasts (47% vs 22.5%, p=.004), markedly increased risk of AML transformation (25.8%, vs. 1.7%, p=.0001) and a worse progression-free survival (PFS) (median 20.3, vs. >50 months, p=.009) than non-R882 mutant MDS cases. …”
    Save to List
    Saved in:
  4. 4
    Image_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif

    Image_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

    Published 2022
    “…Next with the largest cohort of patients with DNMT3A R882 mutant MDS known to date from multiple institutions, DNMT3A R882 mutant MDS cases were shown to have more severe leukopenia, enriched SRSF2 and IDH2 mutations, increased cases with excess blasts (47% vs 22.5%, p=.004), markedly increased risk of AML transformation (25.8%, vs. 1.7%, p=.0001) and a worse progression-free survival (PFS) (median 20.3, vs. >50 months, p=.009) than non-R882 mutant MDS cases. …”
    Save to List
    Saved in:
  5. 5
    Table_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx

    Table_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx by Majd Jawad (12157533)

    Published 2022
    “…Next with the largest cohort of patients with DNMT3A R882 mutant MDS known to date from multiple institutions, DNMT3A R882 mutant MDS cases were shown to have more severe leukopenia, enriched SRSF2 and IDH2 mutations, increased cases with excess blasts (47% vs 22.5%, p=.004), markedly increased risk of AML transformation (25.8%, vs. 1.7%, p=.0001) and a worse progression-free survival (PFS) (median 20.3, vs. >50 months, p=.009) than non-R882 mutant MDS cases. …”
    Save to List
    Saved in:
  6. 6
    Table_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx

    Table_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx by Majd Jawad (12157533)

    Published 2022
    “…Next with the largest cohort of patients with DNMT3A R882 mutant MDS known to date from multiple institutions, DNMT3A R882 mutant MDS cases were shown to have more severe leukopenia, enriched SRSF2 and IDH2 mutations, increased cases with excess blasts (47% vs 22.5%, p=.004), markedly increased risk of AML transformation (25.8%, vs. 1.7%, p=.0001) and a worse progression-free survival (PFS) (median 20.3, vs. >50 months, p=.009) than non-R882 mutant MDS cases. …”
    Save to List
    Saved in:
  7. 7
    Clinical and Imaging Characteristics of Posterior Scleritis in Children

    Clinical and Imaging Characteristics of Posterior Scleritis in Children by Ayala Katzir (20605679)

    Published 2025
    “…Retinal nerve fiber layer (RNFL) was thickened in all examined eyes (mean±SD 136.2 ± 28.4 µm) at presentation and it significantly decreased with treatment (109.8 ± 8.2 µm two months later). …”
    Save to List
    Saved in:

Search Tools: